Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma

F. L. Meyskens, Lois J Loescher, T. E. Moon, B. Takasugi, S. E. Salmon

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We have used the effect of therapeutic agents on clonogenic growth in agar to discriminate between active and inactive agents for malignant melanoma. We report a prospective study of single-agent chemotherapy for metastatic melanoma. Forty-five separate in vitro/in vivo correlative trials were conducted in 34 patients. A number of agents were used in these evaluations, including actinomycin D, Amsacrine, bisantrene, mitoxantrone, BCNU, vinblastine, vindesine, 5-fluorouracil, MGBG, etoposide, interferon, tamoxifen, and 13-cis-retinoic acid. At the 'cut-off' concentration, a colony survival <30% was designated as 'sensitivity' and >30% as 'resistance'. Clinical sensitivity was designated to include complete, partial, and mixed responses and was predicted in eight of 18 trials (44%). Clinical resistance (nonresponse) was predicted correctly in 24 of 27 cases (89%). Using Fisher's exact test the association of in vitro and in vivo results was significant (P=.05). These results offer further support for the concept that clonogenic assays may help select useful agents for clinical trials in metastatic melanoma.

Original languageEnglish (US)
Pages (from-to)1223-1228
Number of pages6
JournalJournal of Clinical Oncology
Volume2
Issue number11
StatePublished - 1984

Fingerprint

Melanoma
bisantrene
Drug Therapy
Survival
Mitoguazone
Amsacrine
Vindesine
Carmustine
Isotretinoin
Mitoxantrone
Vinblastine
Dactinomycin
Therapeutic Uses
Etoposide
Tamoxifen
Fluorouracil
Interferons
Agar
Clinical Trials
Prospective Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma. / Meyskens, F. L.; Loescher, Lois J; Moon, T. E.; Takasugi, B.; Salmon, S. E.

In: Journal of Clinical Oncology, Vol. 2, No. 11, 1984, p. 1223-1228.

Research output: Contribution to journalArticle

@article{5b95422dded244789671f5a64c237fa8,
title = "Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma",
abstract = "We have used the effect of therapeutic agents on clonogenic growth in agar to discriminate between active and inactive agents for malignant melanoma. We report a prospective study of single-agent chemotherapy for metastatic melanoma. Forty-five separate in vitro/in vivo correlative trials were conducted in 34 patients. A number of agents were used in these evaluations, including actinomycin D, Amsacrine, bisantrene, mitoxantrone, BCNU, vinblastine, vindesine, 5-fluorouracil, MGBG, etoposide, interferon, tamoxifen, and 13-cis-retinoic acid. At the 'cut-off' concentration, a colony survival <30{\%} was designated as 'sensitivity' and >30{\%} as 'resistance'. Clinical sensitivity was designated to include complete, partial, and mixed responses and was predicted in eight of 18 trials (44{\%}). Clinical resistance (nonresponse) was predicted correctly in 24 of 27 cases (89{\%}). Using Fisher's exact test the association of in vitro and in vivo results was significant (P=.05). These results offer further support for the concept that clonogenic assays may help select useful agents for clinical trials in metastatic melanoma.",
author = "Meyskens, {F. L.} and Loescher, {Lois J} and Moon, {T. E.} and B. Takasugi and Salmon, {S. E.}",
year = "1984",
language = "English (US)",
volume = "2",
pages = "1223--1228",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma

AU - Meyskens, F. L.

AU - Loescher, Lois J

AU - Moon, T. E.

AU - Takasugi, B.

AU - Salmon, S. E.

PY - 1984

Y1 - 1984

N2 - We have used the effect of therapeutic agents on clonogenic growth in agar to discriminate between active and inactive agents for malignant melanoma. We report a prospective study of single-agent chemotherapy for metastatic melanoma. Forty-five separate in vitro/in vivo correlative trials were conducted in 34 patients. A number of agents were used in these evaluations, including actinomycin D, Amsacrine, bisantrene, mitoxantrone, BCNU, vinblastine, vindesine, 5-fluorouracil, MGBG, etoposide, interferon, tamoxifen, and 13-cis-retinoic acid. At the 'cut-off' concentration, a colony survival <30% was designated as 'sensitivity' and >30% as 'resistance'. Clinical sensitivity was designated to include complete, partial, and mixed responses and was predicted in eight of 18 trials (44%). Clinical resistance (nonresponse) was predicted correctly in 24 of 27 cases (89%). Using Fisher's exact test the association of in vitro and in vivo results was significant (P=.05). These results offer further support for the concept that clonogenic assays may help select useful agents for clinical trials in metastatic melanoma.

AB - We have used the effect of therapeutic agents on clonogenic growth in agar to discriminate between active and inactive agents for malignant melanoma. We report a prospective study of single-agent chemotherapy for metastatic melanoma. Forty-five separate in vitro/in vivo correlative trials were conducted in 34 patients. A number of agents were used in these evaluations, including actinomycin D, Amsacrine, bisantrene, mitoxantrone, BCNU, vinblastine, vindesine, 5-fluorouracil, MGBG, etoposide, interferon, tamoxifen, and 13-cis-retinoic acid. At the 'cut-off' concentration, a colony survival <30% was designated as 'sensitivity' and >30% as 'resistance'. Clinical sensitivity was designated to include complete, partial, and mixed responses and was predicted in eight of 18 trials (44%). Clinical resistance (nonresponse) was predicted correctly in 24 of 27 cases (89%). Using Fisher's exact test the association of in vitro and in vivo results was significant (P=.05). These results offer further support for the concept that clonogenic assays may help select useful agents for clinical trials in metastatic melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0021687248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021687248&partnerID=8YFLogxK

M3 - Article

C2 - 6387058

AN - SCOPUS:0021687248

VL - 2

SP - 1223

EP - 1228

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -